Grail (GRAL) Other financing activities (2023 - 2025)
Grail's (GRAL) quarterly Other financing activities came in at $4.5 million in Q4 2025, down 99.51% quarter-over-quarter from $932.3 million in Q2 2024.
Analysis
Grail (GRAL) Other financing activities (2023 - 2025) Analysis & Trends
Grail (GRAL) has reported Other financing activities for 3 consecutive years, with $4.5 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Other financing activities changed N/A year-over-year to $4.5 million; the trailing twelve-month figure through Dec 2025 stood at $4.5 million (down 99.64% YoY), and the FY2025 full-year result was $4.5 million, down 99.64% from the prior year.
- Other financing activities eased to $4.5 million in Q4 2025 per GRAL's latest filing, from $932.3 million in the prior quarter.
- Across five years, Other financing activities topped out at $932.3 million in Q2 2024 and bottomed at $4.5 million in Q4 2025.
- Historically, Other financing activities has averaged $333.7 million across 3 years, with a median of $199.0 million in 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Natera | 53.05 Bn | 51.95 Bn | 486.15 Mn |
| 2 | Quest Diagnostics | 27.19 Bn | 26.87 Bn | 1.03 Bn |
| 3 | Labcorp Holdings | 25.93 Bn | 25.81 Bn | 1.11 Bn |
| 4 | Guardant Health | 23.97 Bn | 22.91 Bn | 219.03 Mn |
| 5 | Tempus AI | 13.64 Bn | 12.82 Bn | 274.25 Mn |
| 6 | Caris Life Sciences | 8.47 Bn | 7.68 Bn | 182.38 Mn |
| 7 | Sotera Health | 5.35 Bn | 4.99 Bn | 177.96 Mn |
| 8 | BillionToOne | 4.96 Bn | 4.41 Bn | 77.11 Mn |
| 9 | Adaptive Biotechnologies | 4.55 Bn | 4.21 Bn | 51.39 Mn |
| 10 | Grail | 3.61 Bn | 2.75 Bn | 21.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 4.53 Mn |
| Jun 30, 2024 | 932.30 Mn |
| Mar 31, 2024 | 312.00 Mn |
| Dec 31, 2023 | 86.00 Mn |